Semaglutide denied as duplicate or overlapping therapy by Cigna?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Cigna typically requires
Cigna's specific coverage criteria for semaglutide are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Cigna angle on Semaglutide
## Why Cigna May Deny Semaglutide as Duplicate Therapy
A duplicate-therapy denial means Cigna has determined that another medication already on your active claims record serves the same therapeutic purpose as semaglutide. This most commonly arises when a patient has a concurrent claim for another GLP-1 receptor agonist or, in some cases, another agent used for the same labeled indication. The denial is not a judgment about semaglutide itself — it is a utilization-management finding about overlapping coverage.
## Why This Denial Is Appealable
Duplicate-therapy logic depends entirely on the accuracy of Cigna's records and on a valid clinical comparison between the two agents. If the other medication is no longer active, was prescribed for a different indication, or was discontinued, the premise of the denial collapses. Prescribers also frequently have documented clinical reasons — tolerability, efficacy, comorbid conditions — why one agent within a class is not interchangeable with another for a specific patient.
## Your Federal Appeal Rights
- Internal appeal (Level 1): You have the right to a full-and-fair internal review under ERISA §503 (employer plans) or applicable state law (individual/fully-insured plans). Submit within the timeframe shown on your denial notice.
- External review (Level 2): Under ACA §2719, you may escalate to an independent review organization (IRO) if the internal appeal is denied. The standard external-review window is approximately four months from the date of the final internal denial; check your denial letter for the exact deadline.
- Expedited review: If the standard timeline would seriously jeopardize your health, request expedited internal and external review simultaneously.
## Documentation to Gather
1. Active medication list: A current, dated medication list from your prescriber confirming which agents are truly active and for which indications. 2. Discontinuation records: Chart notes or pharmacy records documenting that any overlapping agent has been stopped, including the date and reason. 3. Distinct-indication evidence: If semaglutide is prescribed for a different labeled indication than the other agent, provide diagnosis codes and chart documentation supporting each indication separately. 4. Medical-necessity letter: A signed letter from your prescriber explaining why semaglutide is clinically necessary for you specifically and why the other agent does not serve as an equivalent substitute. 5. Prescribing information: Reference the FDA-approved prescribing label for semaglutide and the FDA label for the alleged duplicate to demonstrate they are not therapeutically identical for your situation.
## Criteria-Mapping Structure
Pull the exact duplicate-therapy criteria from Cigna's published coverage policy for semaglutide. For each criterion listed, provide a direct answer drawn from your chart:
| Cigna Criterion (from policy) | Your Chart Evidence | |-------------------------------|--------------------| | Is another GLP-1 agonist currently active? | [Date of discontinuation or confirmation it was never filled] | | Is the concurrent agent indicated for the same diagnosis? | [Diagnosis codes and prescriber attestation] | | Does the patient have a documented clinical reason for non-interchangeability? | [Prescriber letter citing tolerability, efficacy, or comorbidity rationale] |
Address each criterion in your appeal letter point by point. Vague responses are easy to deny; specific, dated chart facts are much harder to dismiss.
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →